Pure Global AI
NCT05660863Not yet recruiting

A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets

A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Dose of MN-08 in Healthy Subjects
Guangzhou Magpie Pharmaceuticals Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pulmonary Arterial Hypertension
Drug/Device/Intervention
MN-08 24 mg/day
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Guangzhou Magpie Pharmaceuticals Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Jun 01, 2023
End date
Jun 01, 2024
Enrollment
16 participants
Primary outcome

Incidence and severity of TEAEs and SAEs,Incidence and severity of treatment-related adverse events

Summary

This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study
 in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to
 assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5
 consecutive days in healthy subjects.

ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05660863
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05660863 through Pure Global AI's free database. This Phase 1 trial is sponsored by Guangzhou Magpie Pharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.